Everything but amyloid: new thinking prompts FDA revamp

  title={Everything but amyloid: new thinking prompts FDA revamp},
  author={Eva von Schaper},
  journal={Nature Biotechnology},
483 In the midst of another round of grim news for Alzheimer’s disease (AD) drug developers, the US Food and Drug Administration (FDA) issued a draft guidance aimed at helping industry enroll patients in studies using biomarkers, with a clear shift towards earlier stages of the disease. It is one of five guidances for neurological diseases with unmet needs that the agency issued in February. Early Alzheimer’s Disease: Developing Drugs for Treatment recommends enrolling patients into clinical… CONTINUE READING
Twitter Mentions